Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-08
2011-03-08
Ford, Vanessa L. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023700, C424S130100, C424S134100, C424S135100, C424S184100, C424S236100, C424S246100
Reexamination Certificate
active
07902344
ABSTRACT:
The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities forBacillus anthracisantigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection byBacillus anthracis.
REFERENCES:
patent: 5601823 (1997-02-01), Williams et al.
patent: 6329156 (2001-12-01), Cirino et al.
patent: 6916474 (2005-07-01), Harvey et al.
patent: WO 2005/023177 (2005-03-01), None
Maynard et al (Nature Biotechnology, Jun. 2002)See Harlow and Lane, (Antibodies, A laboratory Manual, Cold Springs Harbor Laboratory Publications, 1988).
Maynard et al (Nature Biotechnology, Jun. 2002).
Greenspan et al. (Nature Biotechnology 17: 936-937, 1999).
Cirino et al., “Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors,”Infection and Immunity, 67:2957-2963, 1999.
Maynard et al., In: Abstracts of Papers of 216thNational Meeting of the ACS, Boston, Massachusetts, #212, BIOT, Aug. 23-27, 1998.
Castillo et al., “T7 displayed peptides as targets for selecting peptide specific scFvs from M13 scFv display libraries,”J. Immunol. Methods, 257:117-122, 2001.
Knappik et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,”J. Mol. Biol., 296:57-86, 2000.
Stemmer, “Rapid evolution of a protein in vitro DNA shuffling,”Nature, 370:389-391, 1994.
Walroy et al., “Comparison of four serological methods for the detection of diphtheria anti-toxin antibodies,”J. Immunol. Methods, 245:55-65, 2000.
Bradley et al.,Nature, “Identification of the cellular receptor for anthrax toxin,” 8;414(6860):225-229, 2001.
Bull and Parrich, “A binding contract for anthrax,”Science, 297:201-202, 202, 2002.
Chen and Okayama, “High-efficiency transformation of mammalian cells by plasmid DNA,”Mol. Cell Biol., 7(8):2745-2752, 1987.
Chen et al., “Isolation of high-affinity ligand-binding proteins by periplasmic expression with cyto metric screening,”Nat. Biotechnol., 19:537-542, 2001.
Chen et al., “In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site,”Protein Eng., 12:349-356, 1999.
Creighton,Protein Structure: A Practical Approach, p. 184-186, 1994.
Creighton,Proteins: Structures and Molecular Properties, p. 314-315, 1984.
Daughterty et al., “Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies,”Proc. Natl. Acad. Sci., USA, 97:2029-2034, 2000.
Ezzell et al., “Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components ofBacillus anthracistoxin,”Infect. Immun., 45:761-777, 1984.
Georgiou et al., “Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines,”Nat. Biotechnol., 15:29-34, 1997.
Hayhurst and Georgiou,. “High throughput isolation,”Curr. Opin. Chem. Biol., 5:683-689, 2001.
Hayhurst and Harris, “Escherichia coliSkp chaperone coexpression improves solubility and phage display of single-chain antibody fragments,”Protein Expr. Purif., 15:336-343, 1999.
Hayhurst et al., “Isolation and expression of recombinant antibody fragments to the biological warfare pathogenBrucella melitensis,”J. Immunol. Methods, 276:185-196, 2003.
Hayhurst, “mproved expression characteristics of single-chain Fv fragments when fused downstream of theEscherichia colimaltose-binding protein or upstream of a single immunoglobulin-constant domain,”Protein Expr. Purif., 18:1-10, 2000.
Hoess, “Protein design and phage display,”Chem. Rev., 101:3205-3218, 2001.
Ivins et al., “Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin,”Applies and Environmental Microbiology, 55:2098-2100, 1989.
Keller and Stiehm, “Passive immunity in prevention and treatment of infectious diseases,”Clin. Microbiol. Reviews, 13:602-614, 2000.
Krebber et al., “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system,”J. Immunol. Methods, 201:35-55, 1997.
Leppla, “Anthrax toxin,” Chapter 19 In:Handbook of Experimental Pharmacology, 145:445-472, 2000.
Li et al., “X-ray snapshots of the maturation of an antibody response to a protein antigen,”Nat. Struct. Biol., 10(6):482-488, 2003.
Little et al., “Characterization of lethal factor binding and cell receptor binding domains of protective antigen ofBacillus antracisusing monoclonal antibodies,”Microbiology, 142:707-715, 1996.
Little et al., “Passive protection by polyclonal antibodies againstBacillus antracisinfection in guinea pigs,”Infection and Immunity, 65:5171-5175, 1997.
Little et al., “Production and characterization of monoclonal antibodies to the protective antigen component ofBacillus anthracistoxin,”Infect. Immun., 56:1807-1813, 1988.
Maynard et al., “Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affmity,”Nat. Biotechnol., 20:597-601, 2002.
Maynard et al.,Nature Biotechnology, vol. 20, 2002.
Mourez et al., “Designing a polyvalent inhibitor of anthrax toxin,”Nature Biotechnology, 19:958-961, 2001.
Nosoh et al.,Protein Stability and Stabilization through ProteinEngineering, Chapter 7, p. 197, 1991.
Pitt et al., “In vitro correlate of immunity in a rabbit model of inhalational anthrax,” Vaccine, 19:4768-4773, 2001.
Sellman et al., “Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax,”Science, 292:695-697, 2001.
Singh et al., “A dominant negative mutant ofBacillus antracisprotective antigen inhibits anthrax toxin in vivo,”J. of Biol. Chem., 276:22090-22094, 2001.
Turnbill et al., “Antibodies to Anthrax Toxin in Humans and Guinea Pigs and Their Relevance to Protective Immunity,” Abstract,Med. Microbiol. Immunol., 177:293-303, 1988.
U.S. Appl. No. 10/288,269, filed Nov. 5, 2002.
Wittrup, “The single cell as a microplate well,”Nat. Biotechnol., 18:1039-1040, 2000.
Georgiou George
Harvey Barrett R.
Iverson Brent L.
Ford Vanessa L.
Fulbright & Jaworski L.L.P.
The Board of Regents of the University of Texas System
LandOfFree
Antibodies with increased affinities for anthrax antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies with increased affinities for anthrax antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies with increased affinities for anthrax antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685028